Therefore, to conduct a detailed analysis of these two pathways, we measured the immune cell content in TCGA-PRAD (Fig. 2A) and then analyzed the correlation between TACR2 expression levels and immune cell content (Fig. 2B). Here, TACR2 is linked to prostate adenocarcinoma.